Document is current
Any future updates will be listed below
-
Authors
Herink, Megan C.
Spencer, Hunter C.
Cook, Ryan R.
Gregoire, Devin
Seaman, Andrew
Leichtling, Gillian
Babiarz, Jane
Korthuis, P. Todd
-
Funding
Funding for this research was provided by:
National Institute on Drug Abuse (UH3DA044831, UG1DA015815, K01 DA55130.)
National Institute on Drug Abuse (UH3DA044831, UG1DA015815, K01 DA55130.)
National Institute on Drug Abuse (UH3DA044831, UG1DA015815, K01 DA55130.)
National Institute on Drug Abuse (UH3DA044831, UG1DA015815, K01 DA55130.)
National Institute on Drug Abuse (UH3DA044831, UG1DA015815, K01 DA55130.)
National Institute on Drug Abuse (UH3DA044831, UG1DA015815, K01 DA55130.)
National Institute on Drug Abuse (UH3DA044831, UG1DA015815, K01 DA55130.)
- License Information
-
More Information
Article History
Received: 5 February 2025
Accepted: 19 January 2026
First Online: 5 February 2026
Declarations
:
: The Oregon Health & Science University institutional review board approved the study protocol (version 16) and provided oversight. Informed consent was obtained from all subjects in the study.
: Not applicable.
: Andrew Seaman has participated in investigator-initiated research funded by Merck, Abbvie Pharmaceuticals, and the Gilead Focus Foundation not related to this manuscript. All other authors have nothing to disclose.
